International Clinical Trial: First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527923) titled 'First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis' on April 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Regeneron Pharmaceuticals

Condition: Healthy Volunteer Atopic Dermatitis

Intervention: Drug: REGN20423

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: May 4, 2026

Target Sample Size: 136

To know more, visit https://...